T A Korolenko
Korolenko T, Johnston T, Machová E, Bgatova N, Lykov A, Goncharova N, et al
. Hypolipidemic effect of mannans from C. albicans serotypes a and B in acute hyperlipidemia in mice. Int J Biol Macromol. 2018;107:2385-2394 pubmed publisher
Chang C, Lin T, Ho H, Kuo C, Li H, Korolenko T, et al
. GLP-1 Analogue Liraglutide Attenuates Mutant Huntingtin-Induced Neurotoxicity by Restoration of Neuronal Insulin Signaling. Int J Mol Sci. 2018;19: pubmed publisher
..Our findings collectively suggest that liraglutide can rescue impaired insulin signaling caused by mHTT and that GLP-1 may potentially reduce mHTT-induced neurotoxicity in the pathogenesis of HD. ..
Korolenko T, Pisareva E, Filyushina E, Johnston T, Machová E. Serum cystatin C and chitotriosidase in acute P-407 induced dyslipidemia: Can they serve as potential early biomarkers for atherosclerosis?. Exp Toxicol Pathol. 2015;67:459-66 pubmed publisher
Goncharova N, Shurlygina A, Mel nikova E, Karmatskikh O, Avrorov P, Loktev K, et al
. Cellular Composition of the Spleen and Changes in Splenic Lysosomes in the Dynamics of Dyslipidemia in Mice Caused by Repeated Administration of Poloxamer 407. Bull Exp Biol Med. 2015;160:28-31 pubmed publisher
..The relationship between changes in the cellular composition of the spleen and dynamics of serum lipid profile in mice in dyslipidemia caused by repeated administrations of relatively low doses of poloxamer 407 is discussed. ..
Korolenko T, Johnston T, Tuzikov F, Tuzikova N, Pupyshev A, Spiridonov V, et al
. Early-stage atherosclerosis in poloxamer 407-induced hyperlipidemic mice: pathological features and changes in the lipid composition of serum lipoprotein fractions and subfractions. Lipids Health Dis. 2016;15:16 pubmed publisher
Goncharova N, Khrapova M, Pupyshev A, Korolenko E, Nešéáková Z, Korolenko T. Hypolipidemic Effect of Mannan in Mice with Acute Lipemia Induced by Poloxamer 407. Bull Exp Biol Med. 2016;162:18-22 pubmed
..Thus, mannan from C. albicans is a promising hypolipidemic polysaccharide compound, similar by its activity to ?-glycan, a component of LPS. ..
Gevorgyan M, Voronina N, Goncharova N, Kozaruk T, Russkikh G, Bogdanova L, et al
. Cystatin C as a Marker of Progressing Cardiovascular Events during Coronary Heart Disease. Bull Exp Biol Med. 2017;162:421-424 pubmed publisher
Johnston T, Korolenko T, Pirro M, Sahebkar A. Preventing cardiovascular heart disease: Promising nutraceutical and non-nutraceutical treatments for cholesterol management. Pharmacol Res. 2017;120:219-225 pubmed publisher